57 results found.
Enabling Technology and Integrated Selling Strategies Drove Orthopedic Growth in the Third Quarter
The third quarter of 2019 brought some standout performances from large players like Stryker, Medtronic, NuVasive and Globus Medical. DePuy Synthes and Zimmer Biomet made incremental progress in returning to market growth. Notably, the top performing players all have well-established enabling tec...
Vericel to Expand MACI Salesforce Again on Strong Demand
Vericel reports 3Q19 MACI revenue of USD $20.6MM, +25.3% vs. 3Q18.
Orthopedic Public Companies Grow 2.6% YoY in Quarter
By Mike Evers The second quarter of 2019 brought incremental improvement over the first. Year over year revenue grew 2.6% in the quarter for the public companies reported herein compared to 1.1% last quarter. The five largest orthopedic players, which control 58% of the market, showed a...
Vericel Posts Record Growth in 2Q19 on New Surgeons
Vericel reports 2Q19 MACI revenue of USD $20.8MM, +47.5% vs. 2Q18.
Orthopedic Sales in Line with Seasonal Expectations for 1Q19
By Mike Evers The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies listed herein had combined total orthopedic sales of $8....
Vericel Reports 1Q19 MACI Revenue of $16.6MM, +37% vs. 1Q18
Vericel reports 1Q19 MACI revenue of USD $16.6MM, +37% vs. 1Q18.
Revenue Review: 4Q18 and Full Year 2018 Performance Highlights for Public Companies
By Mike Evers Below you’ll find a summary of the major 4Q18 and full year 2018 developments for publicly-traded orthopedic companies. Exhibits 1 and 2 show 4Q18 and full year performance, respectively.  Companies continue to refine their strategies to improve sales mix ...
Vericel Reports 4Q18 MACI Revenue of $25.1MM, +56% vs. 4Q17
Vericel reports 4Q18 MACI revenue of USD $25.1MM, +56% vs. 4Q17, with 2018 full year reven...
Aesculap Biologics Announces NOVOCART 3D Trial Enrollment Milestone
Aesculap Biologics achieved 50% enrollment in its Phase III clinical trial of NOVOCART® 3D, a...
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Vericel Reports 3Q18 MACI Revenue of $16.4MM, +65.7% vs. 3Q17
Vericel posts another record quarter for MACI with revenue of US $16.4MM, +65.7% vs. 3Q...
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Vericel Posts 2Q18 MACI Revenue Growth
For 2Q18, Vericel posted MACI orthobiologic revenue of US $14.1MM, +9.3% vs. 2Q17, with 1H18 revenue of $26.2MM,...
1H18 Funding Recap: Where'd They All Go?
By Julie A. Vetalice Last year’s 1H review recapped 24 funding announcements. This year, we have 10 to cover. Ten! We'll leave speculation on that drop to more expert handlers. (If you want to share a thought on it, by all means, send me an 
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Vericel Closes $74.8MM Public Offering
Vericel closed its underwritten public offering of 5,750,000 shares of is common stock for $13/share, for gross proceeds o...
Vericel Prices $65MM Public Offering of Stock
Vericel, developer of MACI® autologous cultured chondrocytes for cartilage repair, priced its underwritten public offering of
Vericel Posts MACI 1Q18 Revenue Growth
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
Vericel's MACI Shows Sustained Benefit at Five Years
Study results demonstrated that improvements in pain and function from use of Vericel's MACI vs. microfracture in the treatment...
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Vericel Reports Orthobiologics Growth for 4Q17, 2017
Vericel posted 4Q17 orthobiologic revenue of US $16.1MM, +26.8% vs. 4Q16, and 2017 revenue of $43.9MM...
Vericel Receives First Payment from Innovative Cellular Collaboration
Vericel initiated its Carticel/MACI distribution agreement with Innovative Cellular Therapeutics following a
The Orthopaedic Products and Services of 2017
By Julie A. Vetalice The annual rundown of products and services is like attending a reunion—we’re looking back over the year and keeping you informed on what everyone is doing. Here’s what made headlines with market entry in 2017. We’ll start with services, and ...
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2020 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group